

**PATENTS**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Schrimpf, *et al.*

Serial No.: (not yet assigned)

Filed: March 26, 2004

For: DIAZABICYCLIC CENTRAL  
NERVOUS SYSTEM ACTIVE  
AGENTS

Examiner: (not yet assigned)

Group Art Unit: (not yet assigned)

Case No.: 6696USD1

Express Mail Mailing Label Number  
EV320604349US

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service under 37 C.F.R. 1.10 on the date shown below with sufficient postage addressed to the:

Mail Stop Patent Application  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Date of Deposit: March 26, 2004

Tanya M. Parent 3/26/04  
Tanya M. Parent Date

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form.

Applicants submit herewith the Form PTO-1449 listing the references cited in this Information Disclosure Statement. The listed references are available for the Examiner to review in the file of the U.S. Serial No. 09/833,914. If the Examiner needs further copies of any cited references, the Examiner is respectfully requested to contact the undersigned attorney.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.


ABBOTT LABORATORIES

Customer Number 23492

Telephone: (847) 937-8272

Facsimile: (847) 938-2623

Respectfully submitted,  
Schrimpf, et al.

  
\_\_\_\_\_

Portia Chen

Registration No. 44,075

Attorney for Applicants

## Form PTO - 1449 (Modified)

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)  (37 CFR 1.98 (b))	<b>ATTY. DOCKET NO.</b> <b>6696USD1</b>	<b>SERIAL NO.</b> <b>(not yet assigned)</b>
	<b>APPLICANT(S)</b> <b>M. R. Schrimpf, et al.</b>	
	<b>FILING DATE</b> <b>March 26, 2004</b>	<b>GROUP</b> <b>(not yet assigned)</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,071,999	12/10/1991	Schenke et al.			
	A2	5,382,584	01/17/1995	Balasubramanian			
	A3	5,472,958	12/05/1995	Gunn et al.			
	A4	5,478,939	12/26/1995	Trybulski et al.			
	A5	5,773,912	06/30/1998	Saeki et al.			
	A6	5,914,328	06/22/1999	Lin et al.			
	A7	5,948,793	09/07/1999	Abreo et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
	B1	0 324 543	19.07.1989	EP				
	B2	0 345 808	11.01.1995	EP				
	B3	0 400 661	05.12.1990	EP				
	B4	0 603 887	26.09.1994	EP				
	B5	00/34284	15.06.2000	WO				
	B6	00/44755	03.08.2000	WO				
	B7	00/66586	09.11.2000	WO				
	B8	00/71534	30.11.2000	WO				
	B9	01/44243	21.06.2001	WO				
	B10	94/08922	28.04.1994	WO				
	B11	96/06093	29.02.1996	WO				
	B12	97/05139	13.02.1997	WO				
	B13	99/21834	06.05.1999	WO				
	B14	99/32117	01.07.1999	WO				
	B15	99/51602	14.10.1999	WO				

	B16	95/23152	31.08.95	WO				
	B17	96/31475	10.10.96	WO				
	B18	97/17961	22.05.97	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

	C1	Arneric et al., "Cholingeric channel modulators as a novel therapeutic strategy for alzheimer's disease," Exp. Opin. Invest. Drugs 5(1):79-100 (1996)
	C2	Arneric, et al., "Neuronal Nicotinic Acetylcholine Receptors," Psychopharmacology: The fourth Generation of Progress 95-109 (1995)
	C3	Barlocco et al., J. Med. Chem. 41:674-681 (1998)
	C4	Benowitz, et al., "Pharmacokinetics, metabolism, and pharmacodynamics of nicotine, " Nicotine Psychopharmacology 112-157 (1990)
	C5	Berge, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences 66(1):1-19 (1977)
	C6	Brehm et al., "Glycine antagonists, synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions," J. Med. Chem. 269:224-229 (1986)
	C7	Chem Pharm Bull. 6:408-411 (1958)
	C8	Cherny, "Opioid Analgesics," Drug 51(5):713-737 (1996)
	C9	Cope et al., "Syntheses of D-and L-2,6-diheterobicyclo [3.3.0]octanes," JACS 78:5916-5920 (1956)
	C10	Corey, et al., "A synthetic method for formyl-ehytynyl conversion (RCHO-RC=CH or CR)," Tetrahedron Letters 36:3769-3772 (1972)
	C11	Davidson, et al., "Cholinergic Agonists in alzheimer's Disease Patients," Current Research in Alzheimer Therapy 333-336 (1988)
	C12	Decker et al., "Therapeutic potential of Neuronal Nicotinic Acetylcholine Receptor Agonists As Novel Analgesics," Biochemical Pharmacology 58:917-923 (1999)
	C13	Dormoy, "Synthese Industrielle en serie ellipticine," Tetrahedron 49(14):2885-2914 (1993)
	C14	Dray et al., "New pharmacological strategies for pain relief," Annu. Rev. Pharmacol. Toxicol 36:253-80 (1996)
	C15	Dray, et al., Trends in Pharmacol. Sci. 15:190-197 (1994)
	C16	Gribble, et al., "Regioselective ortho lithiation of halopyridines," Tetrahedron letters 21:4137-4140 (1980)
	C17	Hands, et al., "A convenient method for the preparation of 5-,6 and 7-azaindoles and their derivatives," Synthesis 877-882 (1996)
	C18	IUPAC, Pure and Applied Chemistry 45:13-30
	C19	Jacquet et al., Tetrahedron Letters 32(12):1565-1568 (1991)
	C20	Knight et al., "6-Hydroxypiperidinecarboxylates: additions to the chiral pool from bakers' yeast reduction of beta-ketopiperidinecarboxylates," J. Chem Soc. Perkins Trans. 1:3673-3683 (1998)
	C21	Korczy, "Parkinson's Disease" Psychopharmacology: The Fourth Generation of Progress 126:1479-1484
	C22	Lazar, et al., "Saturated heterocycles, Part 172. Synthesis of 2,6-disubstituted-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine derivatives," J. Heterocyclic Chem. 27:1885-1892 (1990)
	C23	Linstrom, "Nicotinic Acetylcholine Receptors in Health and disease," Molecular Neurobiology 15:193-222 (1997)
	C24	Lloyd et al., "The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents," Life Sciences 62(17/18):1601-1606 (1998)
	C25	Numata, et al., "General synthetic method for naphthyridines and their n-oxides containing isoquinolinic nitrogen," Synthesis 2:306-311 (1999)
	C26	Organic Mass Spectrometry 19(9):459-450 (1984)

C27	Padwa, et al., Organic Synthesis 67:133-140 (1988)
C28	Pebreza et al., Molecular Pharmacology 39:9-12 (1990)
C29	Prescott, Methods in Cell Biology XIV:33-71 (1976)
C30	Reimschuessel, et al., "Studies on new derivatives of caprolactam," Journal of Organic Chemistry 34(4):959-9633 (1969)
C31	Ronn, et al., "Palladium(II)-Catalyzed Cyclization Using Molecular Oxygen as reoxidant," Tetrahedron Letters 36(42):7749-7752 (1995)
C32	Roth, et al, "Biochemical Pharmacology of Midbrain dopamine Neurons," Psychopharmacology: The Fourth Generation of Progress 227-243 (1995)
C33	Salin-Pascual, et al., "Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression," J. Clin. Psychiatry 57:387-389 (1996)
C34	Clayton, et al., "A total synthesis of (±)-Epibatidine," Tetrahedron Letters 36(46):7493-7496 (1993)
C35	Sirisoma, et al., "Alpha-Iodocycloalkenones: synthesis of (±)-Epibatidine, Tetrahedron Letters 39:2059-2062 (1998)
C36	Wagaw, et al., "The synthesis of aminopyridines: A method employing palladium-catalyzed carbon-nitrogen bond formation," J. Org. Chem. 61:7240-4241 (1996)
C37	Williams et al, "Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine," Exp. Opin. Invest. Drugs 5(8):1035-1045 (1996)
C38	Williams, et al., J. Med. Chem. 42(9):1481-1500 (1999)
C39	Wittenberger, et al., "Dialkyltin Oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles," J. Org. Chem. 58:4139-4141 (1993)
C40	Ghelardini et al., "Antinociceptive profile of the new nicotinic agonists DBO-83," Drug Development Research 40:251-258 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

## Form PTO - 1449 (Modified)

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE</b> (Modified) <b>PATENT AND TRADEMARK OFFICE</b>	<b>ATTY. DOCKET NO.</b> <b>6696USD1</b>	<b>SERIAL NO.</b> <b>(not yet assigned)</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>APPLICANT(S)</b> <b>M. R. Schrimpf, et al.</b>	
	<b>FILING DATE</b> <b>March 26, 2004</b>	<b>GROUP</b> <b>(not yet assigned)</b>

(37 CFR 1.98 (b))

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,071,999	12/10/1991	Schenke et al.			
	A2	5,382,584	01/17/1995	Balasubramanian			
	A3	5,472,958	12/05/1995	Gunn et al.			
	A4	5,478,939	12/26/1995	Trybulski et al.			
	A5	5,773,912	06/30/1998	Saeki et al.			
	A6	5,914,328	06/22/1999	Lin et al.			
	A7	5,948,793	09/07/1999	Abreo et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
	B1	0 324 543	19.07.1989	EP				
	B2	0 345 808	11.01.1995	EP				
	B3	0 400 661	05.12.1990	EP				
	B4	0 603 887	26.09.1994	EP				
	B5	00/34284	15.06.2000	WO				
	B6	00/44755	03.08.2000	WO				
	B7	00/66586	09.11.2000	WO				
	B8	00/71534	30.11.2000	WO				
	B9	01/44243	21.06.2001	WO				
	B10	94/08922	28.04.1994	WO				
	B11	96/06093	29.02.1996	WO				
	B12	97/05139	13.02.1997	WO				
	B13	99/21834	06.05.1999	WO				
	B14	99/32117	01.07.1999	WO				
	B15	99/51602	14.10.1999	WO				

B16	95/23152	31.08.95	WO				
B17	96/31475	10.10.96	WO				
B18	97/17961	22.05.97	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

C1	Arneric et al., "Cholingeric channel modulators as a novel therapeutic strategy for alzheimer's disease," Exp. Opin. Invest. Drugs 5(1):79-100 (1996)
C2	Arneric, et al., "Neuronal Nicotinic Acetylcholine Receptors," Psychopharmacology: The fourth Generation of Progress 95-109 (1995)
C3	Barlocco et al., J. Med. Chem. 41:674-681 (1998)
C4	Benowitz, et al., "Pharmacokinetics, metabolism, and pharmacodynamics of nicotine," Nicotine Psychopharmacology 112-157 (1990)
C5	Berge, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences 66(1):1-19 (1977)
C6	Brehm et al., "Glycine antagonists, synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions," J. Med. Chem. 269:224-229 (1986)
C7	Chem Pharm Bull. 6:408-411 (1958)
C8	Cherny, "Opioid Analgesics," Drug 51(5):713-737 (1996)
C9	Cope et al., "Syntheses of D-and L-2,6-diheterobicyclo [3.3.0]octanes," JACS 78:5916-5920 (1956)
C10	Corey, et al., "A synthetic method for formyl-ehynyl conversion (RCHO-RC=CH or CR)," Tetrahedron Letters 36:3769-3772 (1972)
C11	Davidson, et al., "Cholinergic Agonists in alzheimer's Disease Patients," Current Research in Alzheimer Therapy 333-336 (1988)
C12	Decker et al., "Therapeutic potential of Neuronal Nicotinic Acetylcholine Receptor Agonists As Novel Analgesics," Biochemical Pharmacology 58:917-923 (1999)
C13	Dormoy, "Synthese Industrielle en serie ellipticine," Tetrahedron 49(14):2885-2914 (1993)
C14	Dray et al., "New pharmacological strategies for pain relief," Annu. Rev. Pharmacol. Toxicol 36:253-80 (1996)
C15	Dray, et al., Trends in Pharmacol. Sci. 15:190-197 (1994)
C16	Gribble, et al., "Regioselective ortho lithiation of halopyridines," Tetrahedron letters 21:4137-4140 (1980)
C17	Hands, et al., "A convenient method for the preparation of 5-,6 and 7-azaindoles and their derivatives," Synthesis 877-882 (1996)
C18	IUPAC, Pure and Applied Chemistry 45:13-30
C19	Jacquet et al., Tetrahedron Letters 32(12):1565-1568 (1991)
C20	Knight et al., "6-Hydroxypiperidinecarboxylates: additions to the chiral pool from bakers' yeast reduction of beta-ketopiperidinecarboxylates," J. Chem Soc. Perkins Trans. 1:3673-3683 (1998)
C21	Korczyn, "Parkinson's Disease" Psychopharmacology: The Fourth Generation of Progress 126:1479-1484
C22	Lazar, et al., "Saturated heterocycles, Part 172. Synthesis of 2,6-disubstituted-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine derivatives," J. Heterocyclic Chem. 27:1885-1892 (1990)
C23	Linstrom, "Nicotinic Acetylcholine Receptors in Health and disease," Molecular Neurobiology 15:193-222 (1997)
C24	Lloyd et al, "The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents," Life Sciences 62(17/18):1601-1606 (1998)
C25	Numata, et al., "General synthetic method for naphthyridines and their n-oxides containing isoquinolinic nitrogen," Synthesis 2:306-311 (1999)
C26	Organic Mass Spectrometry 19(9):459-450 (1984)

C27	Padwa, et al., Organic Synthesis 67:133-140 (1988)
C28	Pebreza et al., Molecular Pharmacology 39:9-12 (1990)
C29	Prescott, Methods in Cell Biology XIV:33-71 (1976)
C30	Reimschuessel, et al., "Studies on new derivatives of caprolactam," Journal of Organic Chemistry 34(4):959-9633 (1969)
C31	Ronn, et al., "Palladium(II)-Catalyzed Cyclization Using Molecular Oxygen as reoxidant," Tetrahedron Letters 36(42):7749-7752 (1995)
C32	Roth, et al., "Biochemical Pharmacology of Midbrain dopamine Neurons," Psychopharmacology: The Fourth Generation of Progress 227-243 (1995)
C33	Salin-Pascual, et al., "Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression," J. Clin. Psychiatry 57:387-389 (1996)
C34	Clayton, et al., "A total synthesis of (±)-Epibatidine," Tetrahedron Letters 36(46):7493-7496 (1993)
C35	Sirisoma, et al., "Alpha-Iodocycloalkenones: synthesis of (±)-Epibatidine,," Tetrahedron Letters 39:2059-2062 (1998)
C36	Wagaw, et al., "The synthesis of aminopyridines: A method employing palladium-catalyzed carbon-nitrogen bond formation," J. Org. Chem. 61:7240-4241 (1996)
C37	Williams et al, "Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine," Exp. Opin. Invest. Drugs 5(8):1035-1045 (1996)
C38	Williams, et al., J. Med. Chem. 42(9):1481-1500 (1999)
C39	Wittenberger, et al., "Dialkyltin Oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles," J. Org. Chem. 58:4139-4141 (1993)
C40	Ghelardini et al., "Antinociceptive profile of the new nicotinic agonists DBO-83," Drug Development Research 40:251-258 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)